Clinical Trials Logo

Filter by:
NCT ID: NCT03048513 Recruiting - Melioidosis Clinical Trials

Clinical Presentation of Melioidosis in Head and Neck Region

Start date: January 1, 2017
Phase: N/A
Study type: Observational

Melioidosis in head and neck was observed including clinical presentation, diagnosis with titer, and result of treatment.

NCT ID: NCT03048422 Completed - HIV Infections Clinical Trials

Evaluating the Efficacy and Safety of Dolutegravir-Containing Versus Efavirenz-Containing Antiretroviral Therapy Regimens in HIV-1-Infected Pregnant Women and Their Infants

VESTED
Start date: January 19, 2018
Phase: Phase 3
Study type: Interventional

The purpose of this study was to compare the virologic efficacy and safety of three antiretroviral (ARV) regimens, dolutegravir plus emtricitabine/tenofovir alafenamide, dolutegravir plus emtricitabine/tenofovir disoproxil fumarate, and efavirenz/emtricitabine/tenofovir disoproxil fumarate in pregnant women living with HIV-1 and to compare the safety of these regimens for their infants.

NCT ID: NCT03044041 Completed - Clinical trials for Blood Loss, Surgical

Comparison Between Low Dose and High Dose Intra-articular Tranexamic Acid in Total Knee Arthroplasty

Start date: January 2016
Phase: Phase 4
Study type: Interventional

The purpose of this study is to compare blood loss between using low dose (500 mg) and high dose (3 g) topical intra-articular tranexamic acid after total knee arthroplasty in double-blind RCT

NCT ID: NCT03042754 Active, not recruiting - Tuberculosis Clinical Trials

Improve Treatment Outcomes for Tuberculosis Infection in Tertiary Care Hospitals

Start date: June 6, 2011
Phase: N/A
Study type: Interventional

Early diagnosis can contribute to good treatment outcomes and isolate infection control.

NCT ID: NCT03040141 Completed - Influenza A Clinical Trials

Study of Efficacy and Safety of IV VIS410 Plus Oseltamivir Versus Oseltamivir in Hospitalized Adults With Influenza A

Start date: January 3, 2018
Phase: Phase 2
Study type: Interventional

This study is to compare the efficacy and safety of VIS410 in combination with oseltamivir vs oseltamivir alone in severely ill subjects with influenza A infection requiring oxygen support.

NCT ID: NCT03039426 Completed - Cesarean Delivery Clinical Trials

Postoperative Cesarean Delivery Pain Relief; Diclofenac Versus Bupivacaine

Start date: January 1, 2017
Phase: Phase 4
Study type: Interventional

This randomized controlled trial, compared postoperative pain score in patient undergoing cesarean delivery between bupivacaine peritoneal and subcutaneous infiltration and diclofenac intramuscular injection

NCT ID: NCT03038503 Recruiting - Septic Shock Clinical Trials

What Should be the Next Vasopressor for Severe Septic Shock? Methylene Blue or Terlipressin

Start date: December 2016
Phase: Phase 3
Study type: Interventional

The ICU mortality rate of patients with septic shock was still high upto 54.1%.In first 6 hours of resuscitation, the goals of resuscitation in sepsis shock after adequate fluid resuscitation is MAP ≥65 mmHg. In refractory septic shock patient, prolong shock correlate with poor outcome due to multiple organ failure. Alternative vasopressor in septic shock with catecholamine resistance has been studied such as terlipressin, methylene blue - Terlipressin (TP) mediate vasoconstriction via V1 receptors coupled to phospholipase C, and increases intracellular Ca2+ concentration - Methylene blue (MB) directly inhibits nitric oxide synthase (NOS) by inhibit the enzyme guanylate cyclase (GC)

NCT ID: NCT03038113 Completed - Chronic Hepatitis B Clinical Trials

A Study to Evaluate the Safety, Tolerability and Pharmacokinetics and Pharmacodynamics of RO7062931in Healthy Volunteers and Subjects With Chronic Hepatitis B

Start date: February 6, 2017
Phase: Phase 1
Study type: Interventional

This randomized study will be conducted in two parts to evaluate the safety, tolerability, pharmacodynamics, and pharmacokinetics of subcutaneous administration of RO7062931. Part 1 will include only healthy participants and Part 2 will include only participants with chronic hepatitis B (CHB). Part 1 is an adaptive, single-ascending dose study with an adaptive dose-escalating schedule to determine the best dose to be evaluated in participants with CHB. Part 2 is an adaptive, parallel multiple-dose study comprised of three sub-parts which will be used to further refine the dose and dosing regimen, and to evaluate the safety and efficacy of RO7062931 when administered with standard-of-care (SoC) therapy.

NCT ID: NCT03037996 Enrolling by invitation - Clinical trials for Patient Relations, Nurse

To Develop a Validated Program and Use it to Evaluate Patients Post-operatively

Anesthesia
Start date: January 23, 2017
Phase: N/A
Study type: Observational [Patient Registry]

Annually, the Department of Anesthesiology, Siriraj hospital has responsibilities to take care of more than 50,000 patients peri-operatively. According to Maslow's hierarchy of needs; human's pleasure is classified as physiological, safety, belonging, esteem and self-actualization. Since defining and measuring quality of healthcare service is an inevitable challenge for all institutes in medical fields, a questionnaire is developed to assess the quality of all services. The Siriraj Anesthesia Quality Assessment Questionnaire (Si-2-AQ), a simply 40-item tool in seven dimensions, comprises Accessibility and convenience, Communication and Information, Process of care, Technical Quality, Psychological support, Physical support and Royalty.

NCT ID: NCT03037151 Active, not recruiting - Clinical trials for Compensated Cirrhosis

Safety and Efficacy of Grazoprevir and Elbasvir for GT1ang GT6 With and Without HIV

Start date: August 1, 2018
Phase: Phase 4
Study type: Interventional

This study will evaluate the safety and efficacy of combination treatment with grazoprevir + elbasvir for compensated cirrhotic participants with chronic genotype 1 (GT1) and genotype 6 (GT6) hepatitis C virus (HCV) infection with or without human immunodeficiency virus (HIV) infection.